168 related articles for article (PubMed ID: 34075397)
1. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
2. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
3. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
4. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
[TBL] [Abstract][Full Text] [Related]
5. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
6. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
7. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.
Kissil JL; Wilker EW; Johnson KC; Eckman MS; Yaffe MB; Jacks T
Mol Cell; 2003 Oct; 12(4):841-9. PubMed ID: 14580336
[TBL] [Abstract][Full Text] [Related]
8. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
10. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
11. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression.
Rong R; Surace EI; Haipek CA; Gutmann DH; Ye K
Oncogene; 2004 Nov; 23(52):8447-54. PubMed ID: 15378014
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
13. p21-activated kinase links Rac/Cdc42 signaling to merlin.
Xiao GH; Beeser A; Chernoff J; Testa JR
J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
[TBL] [Abstract][Full Text] [Related]
14. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
Kim S; Jho EH
BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
[TBL] [Abstract][Full Text] [Related]
15. Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival.
Pestoni JC; Klingeman Plati S; Valdivia Camacho OD; Fuse MA; Onatunde M; Sparrow NA; Karajannis MA; Fernández-Valle C; Franco MC
J Biol Chem; 2019 Jul; 294(30):11354-11368. PubMed ID: 31171721
[TBL] [Abstract][Full Text] [Related]
16. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
17. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
20. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
